Atlas Trials

The Effects of RPL554 on Top of Standard COPD Reliever Medications

Clinical trial NCT02542254 · COMPLETED

Trial details

NCT number
NCT02542254
Sponsor
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Chronic Obstructive Pulmonary Disease
Start date
2015-10-01
Primary completion
2015-12-01
Enrollment
36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.